| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Monobehenin does not have a specific pharmacological target. It is used as an excipient and formulation aid. It may interact with lipid membranes and affect drug absorption and delivery. It is used in lipid-based drug delivery systems, such as solid lipid nanoparticles and nanostructured lipid carriers.
|
|---|---|
| ln Vitro |
In vitro, monobehenin is used in formulation development and testing. It can be used to prepare lipid nanoparticles, emulsions, and other drug delivery systems. Its effects on cell viability and membrane integrity can be assessed in cell culture models. It is not typically used for biological activity assays.
|
| ln Vivo |
In vivo, monobehenin is used as an excipient in pharmaceutical formulations. It is generally considered safe and is used in oral, topical, and parenteral products. It can affect the bioavailability and pharmacokinetics of drugs when used in lipid-based formulations. It is metabolized to glycerol and behenic acid.
|
| Enzyme Assay |
For non-cellular assays, monobehenin can be characterized using analytical techniques such as HPLC, GC, and DSC. Its purity and composition can be assessed. It can be used in physical chemistry studies to investigate lipid bilayer formation, surface activity, and emulsion stability.
|
| Cell Assay |
For in vitro cell-based assays, monobehenin-containing formulations can be tested for cytotoxicity and cellular uptake using cell culture models. The effects on cell membrane integrity, permeability, and viability can be assessed using standard assays such as MTT, LDH release, and TEER measurements.
|
| Animal Protocol |
For in vivo animal studies, monobehenin-containing formulations can be administered to animals to assess drug delivery, pharmacokinetics, and toxicity. The compound's effects on drug absorption, distribution, metabolism, and excretion can be studied. It is used as an excipient in preclinical formulation development.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties include poor solubility in water and solubility in organic solvents and oils. It is a waxy solid with a melting point around 70°C. It is metabolized to glycerol and behenic acid, which are further metabolized via normal fatty acid pathways. Storage is typically at room temperature, protected from moisture.
|
| Toxicity/Toxicokinetics |
Toxicological data for monobehenin is well-established from its use as a food additive and pharmaceutical excipient. It is generally recognized as safe (GRAS) and has low toxicity. No significant adverse effects have been reported at typical usage levels. It is not for human use in research settings without appropriate approval.
|
| Additional Infomation |
1-Behenylglycerol is a fatty acid ester formed by the condensation of the hydroxyl group at the 1-position of glycerol with the carboxyl group of docosanoic acid. It is a plant metabolite and an antitumor agent. It is a 1-monoglyceride and fatty acid ester, functionally related to glycerol and docosanoic acid. Behenylglycerol has been reported to have been found in Balakata baccata, and relevant data are available.
Monobehenin is a monoacylglycerol used as an emulsifier, stabilizer, and excipient in pharmaceutical and cosmetic formulations. It is also used in food products. It is a component of lipid-based drug delivery systems, such as solid lipid nanoparticles. It is metabolized to glycerol and behenic acid. |
| Molecular Formula |
C25H50O4
|
|---|---|
| Molecular Weight |
414.6621
|
| Exact Mass |
414.371
|
| CAS # |
30233-64-8
|
| PubChem CID |
5362585
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
0.942g/cm3
|
| Boiling Point |
533.8ºC at 760mmHg
|
| Flash Point |
164.6ºC
|
| Index of Refraction |
1.469
|
| LogP |
6.704
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
24
|
| Heavy Atom Count |
29
|
| Complexity |
333
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCCCCCCCCCCCCCCCC(OCC(O)CO)=O
|
| InChi Key |
OKMWKBLSFKFYGZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C25H50O4/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-25(28)29-23-24(27)22-26/h24,26-27H,2-23H2,1H3
|
| Chemical Name |
2,3-dihydroxypropyl docosanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 1 mg/mL (~2.31 mM)
H2O : ~0.1 mg/mL (~0.23 mM) |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4116 mL | 12.0581 mL | 24.1161 mL | |
| 5 mM | 0.4823 mL | 2.4116 mL | 4.8232 mL | |
| 10 mM | 0.2412 mL | 1.2058 mL | 2.4116 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
